RESUMO
BACKGROUND: Users of antipsychotics (APs) have a risk of sudden cardiac death (SCD). Sudden cardiac death in such patients is thought to be largely due to drug-induced QT prolongation. It has been reported that many subjects with drug-induced torsades de pointes (TdP) have risk alleles associated with subclinical congenital long QT syndrome. METHODS: We investigated the effects of the risk alleles associated with long QT on the QT interval in patients receiving APs using 24-hour Holter electrocardiograms to take into account the circadian fluctuation of QT intervals. We investigated 8 single-nucleotide polymorphisms identified on a GWAS. RESULTS: We found that increased numbers of risk alleles at rs7188697 in NDRG4 and rs11970286 in PLN were the major predictors of an increased maximum QT interval over 24 hours in users of APs. CONCLUSIONS: It could be useful to perform a DNA-based analysis before the initiation of APs to reduce the risk of drug-induced torsades de pointes and SCD.
Assuntos
Antipsicóticos/uso terapêutico , Eletrocardiografia Ambulatorial/efeitos dos fármacos , Variação Genética/genética , Estudo de Associação Genômica Ampla/métodos , Frequência Cardíaca/genética , Esquizofrenia/genética , Adulto , Antipsicóticos/farmacologia , Eletrocardiografia Ambulatorial/tendências , Feminino , Variação Genética/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Polimorfismo de Nucleotídeo Único/genética , Esquizofrenia/tratamento farmacológico , Fatores de TempoRESUMO
BACKGROUND: Olanzapine (OLZ) treatment is associated with a high risk of weight gain, and may cause abnormalities in glycolipid metabolism. Therefore, the underlying mechanism of OLZ-related weight gain is needed to clarify but not yet been adequately determined. In recent years, adipocytokines such as leptin, adiponectin, and tumor necrosis factor (TNF)-α, which play important roles in energy homeostasis, have been suggested as biomarkers of weight gain. Here, we determined if baseline plasma concentrations of leptin, adiponectin, and TNF-α predict weight gain following OLZ treatment. METHODS: We recruited 31 schizophrenia outpatients (12 men and 19 women, 28.8 ± 10.2 years old) that were unmedicated or on another antipsychotic monotherapy medication. Baseline body mass index (BMI) and plasma levels of leptin, adiponectin, and TNF-α were obtained. All patients started or were switched to OLZ monotherapy for a maximum of 1 year. BMI was also obtained at the endpoint. RESULTS: Mean BMI change following OLZ treatment was 2.1 ± 2.7 kg/m2. BMI change from baseline to endpoint negatively-correlated with baseline leptin levels in female patients (r = -0.514, P = 0.024), but not male patients. Baseline adiponectin or TNF-α levels were not correlated with BMI change. CONCLUSION: Baseline plasma leptin can have an effect on subsequent weight gain following OLZ treatment in female patients with schizophrenia.
Assuntos
Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Leptina/sangue , Esquizofrenia/tratamento farmacológico , Aumento de Peso/efeitos dos fármacos , Adiponectina/sangue , Adolescente , Adulto , Antipsicóticos/efeitos adversos , Benzodiazepinas/efeitos adversos , Índice de Massa Corporal , Feminino , Humanos , Masculino , Olanzapina , Esquizofrenia/sangue , Fator de Necrose Tumoral alfa/sangue , Adulto JovemRESUMO
Association between gastric inhibitory polypeptide receptor polymorphism, rs10423928, and body mass index in olanzapine-treated schizophrenia was examined. Body mass index change for the A/T+A/A genotypes was significantly higher than that for the T/T genotype. rs10423928 may predict weight gain in schizophrenia.
Assuntos
Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Peso Corporal/genética , Farmacogenética , Polimorfismo de Nucleotídeo Único/genética , Receptores dos Hormônios Gastrointestinais/genética , Esquizofrenia , Adolescente , Adulto , Idoso , Índice de Massa Corporal , Peso Corporal/efeitos dos fármacos , Feminino , Genótipo , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Esquizofrenia/tratamento farmacológico , Esquizofrenia/genética , Esquizofrenia/fisiopatologia , Adulto JovemRESUMO
We investigated the association between remission of depressive symptoms in fluvoxamine treatment and catechol-O-methyltransferase (COMT) gene. Sixteen SNPs in the COMT gene were investigated in 123 outpatients with major depression. Three single nucleotide polymorphisms located in the 5' region were associated with remission in fluvoxamine-treated outpatients with moderate to severe depression.
Assuntos
Antidepressivos de Segunda Geração/administração & dosagem , Catecol O-Metiltransferase/genética , Transtorno Depressivo Maior/tratamento farmacológico , Transtorno Depressivo Maior/enzimologia , Fluvoxamina/administração & dosagem , Regiões Promotoras Genéticas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Resultado do TratamentoRESUMO
AIM: We examined the difference between the effects of olanzapine (OLZ) and risperidone (RIS) on PR and QT intervals among patients with stable schizophrenia using a cohort analysis. METHODS: Twenty-one subjects treated with OLZ were enrolled in the study. Following baseline assessments, which included PR and QT intervals, OLZ was switched to RIS for each subject. The same parameters were evaluated following the switch to RIS. RESULTS: All patients who had been treated with OLZ were successfully switched to RIS. In all patients, we observed a significant decrease in PR interval (t = 2.397, P = 0.029) and no change in either QTc or RR interval. In female patients, the QTc interval was significantly decreased (t = 3.495, P = 0.008) following the switch, while in male patients, the QTc interval did not change. No patients showed a PR interval of >200 ms or a QTc interval of >500 ms. CONCLUSION: OLZ treatment has a greater prolonging effect on PR and QT intervals compared with RIS. Careful attention may need to be paid to the cardiac conduction system in addition to QT prolongation during OLZ treatment.
Assuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Benzodiazepinas/efeitos adversos , Sistema de Condução Cardíaco/efeitos dos fármacos , Risperidona/efeitos adversos , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Benzodiazepinas/uso terapêutico , Estudos de Coortes , Eletrocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Risperidona/uso terapêutico , Caracteres Sexuais , Adulto JovemAssuntos
Antipsicóticos/uso terapêutico , Benzodiazepinas/uso terapêutico , Frequência Cardíaca/efeitos dos fármacos , Síndrome do QT Longo/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/farmacologia , Benzodiazepinas/farmacologia , Eletrocardiografia , Eletroencefalografia , Feminino , Seguimentos , Humanos , Masculino , Olanzapina , Escalas de Graduação Psiquiátrica , Adulto JovemRESUMO
AIMS: In Europe and North America, schizophrenia patients treated with antipsychotic agents have a higher prevalence of obesity and metabolic syndrome compared with healthy individuals. In Japan, the prevalence of overweight/obesity in the general population is considerably lower than that in Europe and North America. The purpose of this study was to investigate the prevalence of underweight and overweight/obesity as well as laboratory data in Japanese inpatients with schizophrenia. METHODS: The subjects were 333 inpatients with schizophrenia and 191 age- and sex-matched healthy volunteers. Overweight/obesity was defined as body mass index (BMI) ≥ 25 kg/m(2) , standard weight was defined as BMI ≥ 18.5 to <25 kg/m(2) and underweight was defined as BMI < 18.5 kg/m(2) . RESULTS: A significant difference in the prevalence of the three BMI levels was observed between schizophrenia patients and controls (P < 0.001). The prevalence of underweight was significantly higher in schizophrenia patients than that in controls (P < 0.001). The prevalence of hypoproteinemia (P < 0.001) and of hypocholesterolemia (P < 0.001) were significantly higher in schizophrenia patients than in controls. In schizophrenia patients, the prevalence of hypotriglyceridemia was significantly higher in the underweight group than in the standard weight group (P = 0.003) and in the overweight/obesity group (P < 0.001). CONCLUSIONS: The prevalence of underweight in Japanese inpatients with schizophrenia may be higher compared with that in the general population. Therefore, the physical health of inpatients should be more carefully taken into account in clinical practice.
Assuntos
Povo Asiático/estatística & dados numéricos , Pacientes Internados/estatística & dados numéricos , Desnutrição/complicações , Desnutrição/epidemiologia , Esquizofrenia/complicações , Magreza/complicações , Magreza/epidemiologia , Adolescente , Adulto , Povo Asiático/psicologia , Índice de Massa Corporal , Estudos de Casos e Controles , Humanos , Pacientes Internados/psicologia , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Obesidade/complicações , Obesidade/epidemiologia , Sobrepeso/complicações , Sobrepeso/epidemiologia , Prevalência , Esquizofrenia/epidemiologia , Adulto JovemRESUMO
BACKGROUND: The prevalence of diabetes in patients with schizophrenia is 2- to 3-fold higher than in the general population. Glucose abnormalities were detected in 11.9% of Japanese schizophrenic patients in a recent cross-sectional study that included fasting glucose monitoring. However, detailed studies of glucose intolerance using the glucose tolerance test have been limited in Japanese patients with schizophrenia. We investigated the prevalence of abnormal glucose tolerance after glucose loading among Japanese inpatients with schizophrenia, with normal fasting glucose levels. METHOD: A total of 258 inpatients with schizophrenia participated in this study after giving their written informed consent. A 75-g oral glucose tolerance test was conducted in the morning after a 12-hour overnight fast. RESULTS: Among patients with normal fasting glucose, 81.3% had normal glucose tolerance, 17.3% had impaired glucose tolerance, and 1.3% were diagnosed with diabetes. CONCLUSIONS: This study showed that the frequency of impaired glucose tolerance in patients with schizophrenia with normal fasting glucose levels might be higher than in the general population. Careful monitoring and screening of patients with schizophrenia for abnormal glucose metabolism might therefore be necessary.
Assuntos
Intolerância à Glucose/epidemiologia , Esquizofrenia/epidemiologia , Adulto , Biomarcadores/sangue , Glicemia/análise , Distribuição de Qui-Quadrado , Jejum/sangue , Feminino , Intolerância à Glucose/sangue , Intolerância à Glucose/diagnóstico , Teste de Tolerância a Glucose , Humanos , Pacientes Internados , Japão/epidemiologia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prevalência , Esquizofrenia/sangue , Esquizofrenia/diagnósticoRESUMO
OBJECTIVE: We examined sex differences in the effect of olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), or quetiapine (QTP) on mean corrected QT (QTc) intervals among 222 patients with schizophrenia. METHODS: Subjects were patients with schizophrenia who were treated with either OLZ (n = 69), RIS (n = 60), ARP (n = 62), or QTP (n = 31). Electrocardiographic measurements were conducted, and the QT interval was corrected using Bazett's correction formula. RESULTS: The mean QTc interval of the QTP group was significantly longer than that of the RIS group (p = 0.002) or ARP group (p = 0.029). The mean QTc interval of the OLZ group was also significantly longer than that of the RIS group (p = 0.006). In female participants, the difference in the mean QTc interval among the four second-generation antipsychotic (SGA) groups was statistically significant (p = 0.002), whereas in male patients, there was no significant difference in the mean QTc interval among the four SGA groups. Post hoc analyses showed that sex differences in QTc interval were observed only in OLZ treatment group (p = 0.007). CONCLUSION: To our knowledge, this is the first study to demonstrate sex differences in the effect of four SGAs on the QTc interval.
Assuntos
Antipsicóticos/uso terapêutico , Síndrome do QT Longo/induzido quimicamente , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Idoso , Antipsicóticos/efeitos adversos , Aripiprazol , Benzodiazepinas/efeitos adversos , Benzodiazepinas/uso terapêutico , Dibenzotiazepinas/efeitos adversos , Dibenzotiazepinas/uso terapêutico , Eletrocardiografia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Olanzapina , Piperazinas/efeitos adversos , Piperazinas/uso terapêutico , Fumarato de Quetiapina , Quinolonas/efeitos adversos , Quinolonas/uso terapêutico , Risperidona/efeitos adversos , Risperidona/uso terapêutico , Fatores Sexuais , Adulto JovemRESUMO
9-Hydroxyrisperidone (9-OH-RIS) is an active metabolite of the antipsychotic drug risperidone (RIS). The total active moiety level, in other words the sum of the RIS and 9-OH-RIS serum levels, may be important for estimating the clinical effects of RIS treatment. However, there have been no consistent results reported regarding the relationship between cytochrome P450 (CYP) 2D6 or adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) variant alleles and 9-OH-RIS or total active moiety plasma levels. Seventy-four Japanese patients treated with RIS were examined in the present study. Steady-state plasma RIS and 9-OH-RIS were measured. The CYP2D6*5, CYP2D6*10, ABCB1 3435C>T, and ABCB1 2677G>T/A genotypes were detected. Multiple regression analysis showed that the dose-corrected plasma RIS levels were significantly correlated with the number of CYP2D6 variant alleles and ABCB1 3435C>T genotypes, whereas the 9-OH-RIS and total active moiety levels were significantly correlated with the ABCB1 3435C>T genotypes and with age. On the other hand, the ABCB1 2677G>T/A genotypes did not affect plasma RIS, 9-OH-RIS, or total active moiety levels. The ABCB1 3435C>T genetic polymorphism may predict plasma 9-OH-RIS and total active moiety levels.
Assuntos
Membro 1 da Subfamília B de Cassetes de Ligação de ATP/genética , Isoxazóis/farmacocinética , Pirimidinas/farmacocinética , Risperidona/farmacocinética , Esquizofrenia/tratamento farmacológico , Subfamília B de Transportador de Cassetes de Ligação de ATP , Adulto , Fatores Etários , Antipsicóticos/farmacocinética , Antipsicóticos/uso terapêutico , Citocromo P-450 CYP2D6/genética , Feminino , Genótipo , Humanos , Japão , Masculino , Pessoa de Meia-Idade , Palmitato de Paliperidona , Polimorfismo Genético , Análise de Regressão , Risperidona/uso terapêutico , Adulto JovemRESUMO
OBJECTIVES: There have so far been few papers studying the metabolic syndrome (MetS) prevalence rate in Japanese patients with schizophrenia. We studied the MetS prevalence rate in Japanese controls and inpatients with schizophrenia and compared the prediction factors for the occurrence of MetS. METHODS: The subjects were 319 inpatients with schizophrenia and 154 controls. The predictive utilities of body mass index (BMI) and the individual components of MetS for MetS diagnosis were evaluated. RESULTS: The prevalence of MetS did not differ between schizophrenia and control subjects. Subjects with schizophrenia showed higher prevalences of the MetS criteria for high-density lipoprotein cholesterol (HDL) (p < 0.001) and waist circumference (WC) (p < 0.001). In subjects with schizophrenia, the predictive power was found to be highest for HDL, followed by WC, BMI, triglyceride, diastolic blood pressure (BP), systolic BP and fasting plasma glucose. However, in control subjects, the predictive power was found to be highest for triglyceride, followed by WC, systolic BP, BMI, HDL, diastolic BP and fasting plasma glucose. HDL was the component most predictive of MetS in subjects with schizophrenia treated with antipsychotics. CONCLUSION: Because, in normal clinical practice, it is difficult to obtain temporal measurements for all of the MetS criteria, measurement of HDL may be useful for predicting the MetS.
Assuntos
Antipsicóticos/efeitos adversos , Povo Asiático/etnologia , Síndrome Metabólica/induzido quimicamente , Síndrome Metabólica/etnologia , Esquizofrenia/etnologia , Adulto , HDL-Colesterol/sangue , Feminino , Humanos , Masculino , Síndrome Metabólica/sangue , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prevalência , Fatores de Risco , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Circunferência da Cintura/fisiologiaRESUMO
Although second-generation antipsychotics (SGAs) are characterized by fewer prolactin (PRL)-related side effects compared with first-generation antipsychotics, the detailed effects of SGAs on the plasma PRL levels still remain unclear. We examined the differences in plasma PRL levels among 268 patients treated for schizophrenia with olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), quetiapine (QTP), or perospirone (PER). The participants had received antipsychotic monotherapy with stable doses of OLZ, RIS, ARP, QTP, or PER for ≥ 3 weeks, and fasting blood samples were drawn to examine plasma PRL levels. The differences in median plasma PRL levels in all (P<0.001), male (P<0.001) and female patients (P<0.001) among the five SGA groups were statistically significant. A stepwise multiple regression analysis showed that ARP treatment was found to contribute to lower plasma PRL level, while female sex, RIS, OLZ and chlorpromazine equivalent dose were found to contribute to a higher plasma PRL level. The median value of plasma PRL level in the RIS group was twice as much compared with that in the OLZ group, although this was not statistically significant. In this study, OLZ had a considerable effect on plasma PRL level, similar to RIS, while PER did not affect plasma PRL levels, similar to QTP. Further studies are needed to clarify the differences in plasma PRL levels among SGAs.
Assuntos
Antipsicóticos/uso terapêutico , Prolactina/sangue , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Adolescente , Adulto , Idoso , Antipsicóticos/classificação , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Análise de Regressão , Fatores de Tempo , Adulto JovemRESUMO
People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.
Assuntos
Antipsicóticos/uso terapêutico , Doenças Cardiovasculares/sangue , Lipídeos/sangue , Esquizofrenia/tratamento farmacológico , Doenças Cardiovasculares/complicações , Humanos , Esquizofrenia/sangue , Esquizofrenia/complicaçõesRESUMO
OBJECTIVES: There are few reports regarding quetiapine (QTP)-related QT prolongation. We examined the change in QT interval after switching from aripiprazole (ARP), olanzapine (OLZ), or risperidone (RIS) to QTP. METHODS: Twenty subjects treated with ARP, OLZ, or RIS were enrolled in the study. Following baseline assessments, which included QT interval and electrolytes, these three drugs were switched to QTP for each subject. The same parameters were evaluated following a switch to QTP. RESULTS: All 20 patients who had been treated with ARP, OLZ, or RIS were successfully switched to QTP. Significant increases were observed in the total mean corrected QT (QTc) interval after switching (p = 0.014). The coefficient of variation for the extent of change in QTc interval was 1.66. The mean QTc with ARP treatment was significantly increased after QTP treatment (p = 0.004). CONCLUSIONS: Quetiapine might have a greater effect on QTc interval than other second-generation antipsychotics. However, because there was a considerable variability in the extent of QTc prolongation after switch to QTP, further studies are required to clarify the effect of QTP on QTc interval.
Assuntos
Antipsicóticos/uso terapêutico , Povo Asiático , Dibenzotiazepinas/uso terapêutico , Substituição de Medicamentos , Frequência Cardíaca/efeitos dos fármacos , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/farmacologia , Povo Asiático/etnologia , Dibenzotiazepinas/farmacologia , Substituição de Medicamentos/métodos , Eletrocardiografia/efeitos dos fármacos , Feminino , Frequência Cardíaca/fisiologia , Humanos , Masculino , Pessoa de Meia-Idade , Fumarato de Quetiapina , Esquizofrenia/etnologia , Esquizofrenia/fisiopatologia , Adulto JovemRESUMO
The development of impaired glucose tolerance induced by antipsychotics (APs) is of concern as a serious adverse effect of psychiatric drug therapy. However, the mechanism by which APs cause dysfunction of the glucose-insulin response is not fully understood. Recent studies have shown that patients treated with APs for schizophrenia were more likely to exhibit impaired glucose tolerance after a glucose load compared with healthy control subjects, even if fasting glucose levels were within the reference range. To explain these findings, we hypothesized that insulin secretion is increased in schizophrenic patients treated with AP, even those normal fasting glucose (NFG) levels. Therefore, oral glucose tolerance tests were conducted in 159 Japanese inpatients with AP-treated schizophrenia and in 90 healthy subjects without schizophrenia. Plasma glucose and serum insulin concentrations were measured before (0 minute) and at 30, 60, 90, and 120 minutes after the oral glucose load. Although insulin levels at 0 minute were similar in both groups of subjects, insulin levels were significantly higher in the patients treated with AP at all times after the glucose load than in the healthy subjects. In analyses of NFG subjects, insulin levels were significantly higher in the patients treated with AP compared with the healthy subjects at all times after glucose loading. Overall, we found that insulin secretion in response to a glucose load was significantly higher in the patients treated with AP, irrespective of NFG. These results suggest that APs affect the glucose-insulin response, which may lead to subclinical insulin resistance before the onset of overt glucose intolerance.
Assuntos
Antipsicóticos/uso terapêutico , Glicemia/metabolismo , Jejum/sangue , Insulina/metabolismo , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Adulto , Antipsicóticos/sangue , Povo Asiático/etnologia , Glicemia/efeitos dos fármacos , Feminino , Teste de Tolerância a Glucose/métodos , Humanos , Insulina/sangue , Resistência à Insulina/etnologia , Secreção de Insulina , Masculino , Esquizofrenia/etnologia , Resultado do TratamentoAssuntos
Antipsicóticos/efeitos adversos , Dibenzotiazepinas/efeitos adversos , Resistência à Insulina/fisiologia , Piperazinas/efeitos adversos , Piperidinas/efeitos adversos , Circunferência da Cintura/efeitos dos fármacos , Redução de Peso/efeitos dos fármacos , Antipsicóticos/uso terapêutico , Dibenzotiazepinas/uso terapêutico , Feminino , Homeostase , Humanos , Piperazinas/uso terapêutico , Piperidinas/uso terapêutico , Fumarato de Quetiapina , Esquizofrenia/complicações , Esquizofrenia/tratamento farmacológico , Adulto JovemRESUMO
OBJECTIVE: The sum of the serum levels of risperidone (RIS) and 9-hydroxyrisperidone (9-OH-RIS), which is the active moiety serum level, could be important for estimating the clinical effects of RIS. However, there have been no consistent results reported about the relationship between cytochrome P450 (CYP) 2D6*10 allele and plasma 9-OH-RIS or active moiety levels. We investigated the effect of the number of CYP2D6*10 alleles on steady-state plasma RIS, 9-OH-RIS, and active moiety levels in Japanese patients. METHODS: Steady-state plasma RIS, 9-OH-RIS, and active moiety levels were measured in 64 patients treated with an average dosage of 4.6 mg/day. RESULTS: The number of CYP2D6*10 alleles significantly affected dose-corrected plasma RIS levels (p = 0.001), and the median concentrations in ng/ml/mg were 0.94 (0 allele) vs. 1.73 (1 allele) vs. 3.05 (2 alleles). The number of CYP2D6*10 alleles did not affect plasma 9-OH-RIS or active moiety levels. CONCLUSION: The present study shows that the number of CYP2D6*10 alleles affected plasma RIS levels but not plasma 9-OH-RIS and plasma active moiety levels. Because the plasma active moiety levels can influence antipsychotic effects or side effects, the genetic screening of the CYP2D6*10 allele for RIS in Asian populations may not be clinically important.
Assuntos
Antipsicóticos/farmacocinética , Citocromo P-450 CYP2D6/genética , Risperidona/farmacocinética , Adulto , Alelos , Antipsicóticos/metabolismo , Feminino , Humanos , Isoxazóis/sangue , Japão , Masculino , Pessoa de Meia-Idade , Palmitato de Paliperidona , Transtornos Psicóticos/tratamento farmacológico , Pirimidinas/sangue , Risperidona/metabolismo , Esquizofrenia/tratamento farmacológico , Adulto JovemAssuntos
Antipsicóticos/efeitos adversos , Antipsicóticos/uso terapêutico , Dibenzotiazepinas/efeitos adversos , Hipoglicemia/tratamento farmacológico , Piperazinas/uso terapêutico , Piperidinas/uso terapêutico , Feminino , Humanos , Hipoglicemia/induzido quimicamente , Pessoa de Meia-Idade , Fumarato de QuetiapinaRESUMO
OBJECTIVE: The underlying mechanism for second-generation antipsychotic (SGA)-related glucose-lipid metabolic dysfunction is not fully understood. Recent studies have suggested a possible impact of SGAs on endocrine regulation, especially on adipocytokines. We examined the effect of each SGA on various adipocytokines in normal fasting glucose (NFG) subjects. METHOD: The study population comprised 113 Japanese inpatients with schizophrenia who were treated with olanzapine, risperidone, or quetiapine, and 123 healthy control (CONT) volunteers. All of the subjects were diagnosed with NFG. Plasma concentration of adiponectin, leptin, tumor necrosis factor α, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol were compared between the SGA and CONT groups. RESULTS: Second-generation antipsychotic subjects had significantly higher leptin levels in comparison to the CONT subjects. The plasma concentration of adiponectin, total cholesterol, and high-density lipoprotein cholesterol in the SGA subjects were significantly lower than those in the CONT subjects. There were no significant differences in tumor necrosis factor α, triglyceride, and low-density lipoprotein cholesterol levels between the 2 groups. In a stepwise multiple regression analysis, olanzapine was found to be a factor that contributed to decreased adiponectin levels, and the CONT subjects were detected to be a factor associated with lower leptin levels. CONCLUSIONS: The present study indicates the possibility that the administration of SGAs may affect adipocytokines in the NFG stage, excluding the impaired fasting glucose group, which is in the transition stage into diabetes mellitus.
Assuntos
Antipsicóticos/efeitos adversos , Leptina/sangue , Esquizofrenia/sangue , Esquizofrenia/tratamento farmacológico , Regulação para Cima/efeitos dos fármacos , Adiponectina/sangue , Adolescente , Adulto , Antipsicóticos/uso terapêutico , Benzodiazepinas/efeitos adversos , Benzodiazepinas/uso terapêutico , Glicemia/análise , Estudos Transversais , Manual Diagnóstico e Estatístico de Transtornos Mentais , Dibenzotiazepinas/efeitos adversos , Dibenzotiazepinas/uso terapêutico , Regulação para Baixo/efeitos dos fármacos , Feminino , Humanos , Resistência à Insulina , Masculino , Pessoa de Meia-Idade , Olanzapina , Fumarato de Quetiapina , Risperidona/efeitos adversos , Risperidona/uso terapêutico , Esquizofrenia/imunologia , Adulto JovemRESUMO
OBJECTIVE: Antipsychotic-treated schizophrenia patients are susceptible to dyslipidemia. However, the results of previous studies of North American and UK populations including various races have been contradictory with regard to which lipid measure was the most affected in patients with schizophrenia taking antipsychotic agents. The aim of this study was to investigate the effect of schizophrenia patients receiving antipsychotic agents on each lipid measure in a Japanese population. METHODS: The samples included 136 control individuals and 157 patients with schizophrenia treated with antipsychotic agents. Age, gender distribution and body mass index (BMI) of the controls were matched with the patients. RESULTS: The high-density lipoprotein cholesterol (HDL-cholesterol) levels were significantly lower in patients than in the control subjects (P<.001). However, there were no significant differences in either the low-density lipoprotein cholesterol (LDL-cholesterol) or triglyceride levels between the patient and control groups. We performed a multiple linear regression analysis, and schizophrenia receiving antipsychotics was an independent predictor of decreased HDL-cholesterol. An increased BMI, male gender and cigarette smoking were also major predictors of a decreased HDL-cholesterol level (r(2)=0.42, P<.001). CONCLUSION: At least in Japanese with schizophrenia receiving antipsychotic agents, the HDL-cholesterol levels should be closely monitored in all patients, even those who are not obese or do not smoke, to decrease their risk of cardiovascular disease.